First 4 doses upon injection shooting pain, Down arm to wrist; First 4 doses upon injection shooting pain, Down arm to wrist; pain in arm 4-5 hours; pounding headache 3-4 hours; intermittent visual focus disturbances 5-6 hours; general malaise 6 hours; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 15Apr2022 at 10:00 as dose 4 (booster), single (Lot number: FK9893), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: penicillin" (unspecified if ongoing); "Known allergies: sulfa" (unspecified if ongoing); "Known allergies: other antibiotics topical" (unspecified if ongoing), notes: other antibiotics topical; "Known allergies: additives in eye drops" (unspecified if ongoing), notes: additives in eye drops; "digestive issues (food allergies)" (unspecified if ongoing); "sinusitis (food allergies)" (unspecified if ongoing); "eustacian tube inflammation" (unspecified if ongoing); "Uticaria from eye drops" (unspecified if ongoing), notes: from eye drops. Concomitant medication(s) included: ARMOUR THYROID. Past drug history included: Neomycin, reaction(s): "Known allergies: Neomycin"; Neomycin, reaction(s): "Urticaria". Vaccination history included: BNT162b2 (Dose 1, Single, Lot number: EN6208, Administration time: 11:45 AM, Anatomical location: Right arm), administration date: 11Mar2021, for COVID-19 Immunization, reaction(s): "Malaise", "injection shooting pain", "continued pain in arm 4-5 hours", "injection shooting pain down arm to wrist", "Headache", "intermittent visual focus disturbances 5-6 hours"; BNT162b2 (Dose 2, single, Lot number: ER8737, Anatomical location: Right arm), administration date: 01Apr2021, for COVID-19 Immunization, reaction(s): "Malaise", "injection shooting pain", "continued pain in arm 4-5 hours", "injection shooting pain down arm to wrist", "Headache", "intermittent visual focus disturbances 5-6 hours"; BNT162b2 (Dose 3 (Booster), single, Lot number: FE3590, Anatomical location: Right arm), administration date: 20Oct2021, for COVID-19 Immunization, reaction(s): "Malaise", "injection shooting pain", "continued pain in arm 4-5 hours", "injection shooting pain down arm to wrist", "Headache", "intermittent visual focus disturbances 5-6 hours". The following information was reported: MALAISE (non-serious), outcome "recovered", described as "general malaise 6 hours"; VACCINATION SITE PAIN (non-serious), ARTHRALGIA (non-serious), outcome "recovered" and all described as "First 4 doses upon injection shooting pain, Down arm to wrist"; PAIN IN EXTREMITY (non-serious), outcome "recovered", described as "pain in arm 4-5 hours"; HEADACHE (non-serious), outcome "recovered", described as "pounding headache 3-4 hours"; VISUAL IMPAIRMENT (non-serious), outcome "recovered", described as "intermittent visual focus disturbances 5-6 hours". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of malaise, vaccination site pain, arthralgia, pain in extremity, headache, visual impairment.  Additional information: Patient did not receive any other vaccine in four weeks. Patient had no COVID prior to vaccination. Patient tested for COVID post vaccination. Test type was nasal swab, COVID PCR test with negative result on 27Jun2021.  No follow-up attempts are possible. No further information is expected.